ALK and mesenchymal cell neoplasm: The patient diagnosed with primary pulmonary <i>ALK</i>-rearranged mesenchymal neoplasm (PPAMN) received ensartinib as postoperative adjuvant therapy, achieving a disease-free survival of 10 months.